These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 25770114

  • 1. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.
    Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T.
    Ann Pharmacother; 2015 Jun; 49(6):674-87. PubMed ID: 25770114
    [Abstract] [Full Text] [Related]

  • 2. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.
    Macías J, Monge P, Mancebo M, Merchante N, Neukam K, Real LM, Pineda JA.
    HIV Med; 2017 Aug; 18(7):445-451. PubMed ID: 27882706
    [Abstract] [Full Text] [Related]

  • 3. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
    Roncero C, Villegas JL, Martínez-Rebollar M, Buti M.
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
    [Abstract] [Full Text] [Related]

  • 4. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection.
    El-Sherif O, Khoo S, Solas C.
    Curr Opin HIV AIDS; 2015 Sep; 10(5):348-54. PubMed ID: 26248122
    [Abstract] [Full Text] [Related]

  • 5. Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.
    Esposito I, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Benítez-Gutiérrez L, Peña JM, Soriano V.
    Expert Opin Drug Saf; 2015 Sep; 14(9):1421-34. PubMed ID: 26212044
    [Abstract] [Full Text] [Related]

  • 6. Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients.
    Poizot-Martin I, Naqvi A, Obry-Roguet V, Valantin MA, Cuzin L, Billaud E, Cheret A, Rey D, Jacomet C, Duvivier C, Pugliese P, Pradat P, Cotte L, Hepadat'AIDS Study Group.
    PLoS One; 2015 Sep; 10(10):e0141164. PubMed ID: 26488159
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease.
    Kwo PY, Badshah MB.
    Curr Opin Organ Transplant; 2015 Jun; 20(3):235-41. PubMed ID: 25944238
    [Abstract] [Full Text] [Related]

  • 10. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.
    McConachie SM, Wilhelm SM, Kale-Pradhan PB.
    Expert Rev Clin Pharmacol; 2016 Jun; 9(2):287-302. PubMed ID: 26651915
    [Abstract] [Full Text] [Related]

  • 11. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.
    Talavera Pons S, Boyer A, Lamblin G, Chennell P, Châtenet FT, Nicolas C, Sautou V, Abergel A.
    Br J Clin Pharmacol; 2017 Feb; 83(2):269-293. PubMed ID: 27530469
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection.
    Toussaint-Miller KA, Andres J.
    Ann Pharmacother; 2015 Sep; 49(9):1015-30. PubMed ID: 26139639
    [Abstract] [Full Text] [Related]

  • 14. Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.
    Meemken L, Hanhoff N, Tseng A, Christensen S, Gillessen A.
    Ann Pharmacother; 2015 Jul; 49(7):796-807. PubMed ID: 25902733
    [Abstract] [Full Text] [Related]

  • 15. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M, Hill L, Kerr J.
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment.
    Hill L.
    Top Antivir Med; 2015 Dec; 23(2):92-6. PubMed ID: 26200709
    [Abstract] [Full Text] [Related]

  • 17. Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?
    Cervino L, Hynicka LM.
    Ann Pharmacother; 2018 Nov; 52(11):1152-1157. PubMed ID: 29681166
    [Abstract] [Full Text] [Related]

  • 18. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L, Lai A, Calvi E, Ronzi P, Micheli V, Binda F, Ridolfo AL, Gervasoni C, Galli M, Antinori S, Sollima S.
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
    Deming P, Martin MT, Chan J, Dilworth TJ, El-Lababidi R, Love BL, Mohammad RA, Nguyen A, Spooner LM, Wortman SB.
    Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
    [Abstract] [Full Text] [Related]

  • 20. How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?
    Saeed S, Strumpf EC, Walmsley SL, Rollet-Kurhajec K, Pick N, Martel-Laferrière V, Hull M, Gill MJ, Cox J, Cooper C, Klein MB, Canadian Co-Infection Cohort Study, Cohen J, Conway B, Cooper C, Côté P, Cox J, Gill J, Haider S, Harris M, Haase D, Hull M, Montaner J, Moodie E, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall JM, Vachon ML, Walmsley S, Wong D.
    Clin Infect Dis; 2016 Apr 01; 62(7):919-926. PubMed ID: 26743093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.